Judge Hacks Away At Allergan's Restasis Patents

Law360, New York (October 16, 2017, 6:11 PM EDT) -- A federal judge ruled Monday that claims in several patents covering Allergan PLC’s dry-eye drug Restasis are invalid, dealing a blow to the drugmaker just weeks after it transferred the patents to a Native American tribe in an effort to shield them from review at the Patent Trial and Appeal Board.

The ruling is a significant step in allowing generics makers to sell their own versions of Allergan's Restasis, which generated about $1.5 billion in revenue last year. (AP) Senior U.S. Circuit Judge William Bryson issued...
To view the full article, register now.